Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Divergent accum/dist line with the price per share the last 4 months or so, coiled up. This will move soon enough, they might hold approval news until the president is online in Nov.
Once this science reaches the marketable stage of development, it won't matter if George Kostanza was running the company. Look at Ichim's previous accomplishments and understand what a lot of savvy investors are posting on these boards instead of knocking yourself around in your head all the time, Biotech investing is a tough endeavor.
Recent pr, imo, is another brick in the wall and not the finished product. The company isn't pr'ing to sell shares but to inform. There is a difference... a diversified immuno-onc portfolio being built to justify a co-development deal for an IND which could look like an upfront multi-million payment along w/ a milestone payment schedule or a license deal on IP patents held. a license in the 100 mil range could hit here at any time imo.
Goonies never say die!
True, his statement referred to the big board but this is the OTC where investor sentiment can change at any moment, i am confident BMSN will see an adrenaline shot of volume in the near future that will wake her up like Uma Thurman in Pulp Fiction, Just need Koos to forcefully hit the red circle!
Alan Leong, Biowatch news founder, a professional biotech analyst....stated in a 2015 online article: Wall Street typically gives biotechs a $250 million valuation for an FDA approved PH I IND. RGBP/BMSN has two about to reach this milestone. We could start to see a climb to a $500 million valuation, perhaps more as hema/dcell are immunotherapy based, this sector since 2014 has seen strong demand, BMSN .03-.05, may take a couple high volume days at first before moving north
In my dreams 42,000 % in a day lol, nice to see though, up 800% since the R/S consolidating for the next leg up. With such a small float, ENTB cant be held down, have a good weekend longs, blast off news on the way!
ENTBD 17m o/s with two new products in a 15bil under represented market about to make a huge move...radar if looking for a mid term hold...sister company on verge for FDA clinical trial approval (sept/Oct) will have impact. Recent R/S caused a share recount, last two weeks trading shows a massive short squeeze taking place
ENTBD 17m o/s with two new products in a 15bil under represented market about to make a huge move...radar if looking for a mid term hold...sister company on verge for FDA clinical trial approval (sept/Oct) will have impact. Recent R/S caused a share recount, last two weeks trading shows a massive short squeeze taking place
ENTBD 17m o/s with two new products in a 15bil under represented market about to make a huge move...radar if looking for a mid term hold...sister company on verge for FDA clinical trial approval (sept/Oct) will have impact. Recent R/S caused a share recount, last two weeks trading shows a massive short squeeze taking place
I would imagine, Zander will develop into not so much an intellectual property incubator for medical discovery like the sisters but more as a business venture for two market ready veterinarian products, we need to see upcoming business model plans for the business infrastructure build and marketing/distribution plan, how are they gonna start up sales, local san diego / SoCal markets from what i've seen in LA, are hungry for these products along with rest of the nation. I would endorse Paris Hilton as the spokeswoman...
ENTBD vet nanotech oncology platform, 17 million float close to locked up, moving fast
ENTBD vet nanotech oncology platform, 17 million float close to locked up, moving fast
Exciting developments! Platforms will find a huge demand, Zander about to grow exponentially! Nanotech delivery method a game changer for potency against cancer and leukemia, looking forward to seeing revenues ASAP!
Reasonable to consider 27Jul as a timeframe for FDA approval news on hema along with nano deal finalized, Koos preparing ENTB to run along with RGBP...so many possibilities here, looking forward to finding out
ENTB about ready to rock? Looks like Dr Koos is holding a Royal Flush and the OTC is heating up with the summer sun! About ready for the showdown here, load em up!
Koos and Ichim have known for months now that the CRL safety results are the final FDA requirement, why not push the orphan application up through the OOPD while they wait to hear back from CRL or prepare the orphan application and send it along with the CRL results, that would place the IND in a rapid ph I/II development trajectory with plenty of fuel for our trip into the stratosphere
When otc stocks run, they run w/ irrational exuberance, w/ a couple well placed catalysts that are in the works at rgbp, bmsn could easily hit .10 as investors see the undervalue here, then a pullback to a sustainable level, the run here will be worth the wait, is why you see so many longs w the Koos trifecta
Koos' strategy for entb made a move today, his intent with BMSN not yet, but it is there long term...investing in the biotech sector is not a game of checkers, more a game of chess, once you understand the moves and strategy you can see the checkmate, rgbp about to have the fda in check
Definitely agree, looking at the similarities of aplastic anemia to MDS to Leukemia and the complimentary therapies under development, willing to bet the Ichims have something up their sleeves with telomere research that relates to these afflictions and may apply to an even broader market
Telomere potential, the last paragraph, author does not know about Regen's treatment
http://www.cbsnews.com/news/changes-in-the-blood-can-predict-cancer/
Main stream media outlets lighting up with cancer treatment discovery news in parallel w AACR, exciting times, reading through some of the articles helped me understand CEOs recent comments about near and long term, Regen is aiming up to become a major/essential puzzle piece in a big pharma combination therapy, sounds like CEO has some strategizing and big decisions ahead, no doubt there are multiple puzzles where he can take the key-master! Cheers all for being early to the party.
http://m.medicalxpress.com/news/2015-04-team-master-cancer-causing-her2-protein.html
Dr Kesari is developing a similar treatment except he is injecting the herpes virus instead of polio, Regen could acquire the patent in the future
It's possible, whomever Regen selects as the CRO for the GLP safety experiment will also be the same organization that will provide a principal investigator and conduct the clinical trials...the continuity may speed things along and allow Regen to focus on the Orphan application, when the pace of development will really accelerate
Oh yeah sizzle, entb gonna rocket!!!
2006 NYTs article discussing Cancer stem cell importance, leaps and bounds have been made in the 9 years since this article
http://www.nytimes.com/2006/02/21/health/21canc.html?ex=1298178000&en=6de257099a800e66&ei=5088&partner=rssnyt&emc=rss&_r=0
Dr John Dick, possibly a Professor for the Ichims at UoT?
Alot of time and effort went into their preparation, now they are ready to present their case to the scientific world that there now exists a viable fourth option to cancer treatment, surgery, chemo, radiation and now immunotherapy targeted cancer stem cells, Regen is a pioneer, investors here know this, the time to buy in cheap is quickly closing
She discovered a new ONCOGENE, has a method to target it and Regen owns the patent rights.
The OTC does not realize the value and impact of that...yet.
From previous PRs, the NR2F6/NR2F2 oncogenes have never before been targeted as a cancer therapuetic, let alone targeted by a hybrid differentiation for MDS like is being proposed.
Today’s PR addresses cancer cells ability to evolve/mutate or resist drugs that are a threat, consideration for NR2F2 as a preventative measure, shows Dr. Ichim's foreknowledge and expertise in her research and development procedures, laying the foundation for a solid IND.
The Ken Burn's special (end of part II and III), focused on previous targeted therapeutics success,Gleevec/Herceptin....these are billion dollar + blockbuster drugs…they provide a great reference to see how cancer medicine has evolved in only the last 10 years. …NR2F6/NR2F2/BORIS is a leading example of this evolution that could break a previously undiscovered pathway and lead to several follow on therapeutics moving forward.
Aplastic anemia can evolve into MDS, MDS into leukemia (AML)….a combination therapy with hemaxellerate may be a long term goal for the company or part of a package license agreement, combinations have proven to be the most effective means in fighting cancer. Co-development with BORIS IP, will increase the effective potency. Infusion with the benitec platform is less invasive than bone marrow transplant and chemo, would be more desirable for older patients, an expanding population. MDS qualifies for Orphan drug status, see APG101. …
I believe this is partially the reason why we are seeing a lot of interest at the professional conferences. The question is not so much will this receive IND FDA approval, but how effective and safe will it prove out in humans. What toxicity factors will need to be addressed. A co-development deal could be executed before an IND…
Stem cell research was founded at the University of Toronto in the 1960’s, Regen Scientists’ alma matter. Cancer researchers like these are the unsung heroes in the fight against cancer.
All IMO on current developments w/ a quick Wikipedia search.
lol thinking the same, was researching to better understand NR2F6 and differentiation therapy and up popped the abstract on the AACR website. Standing by for further clarification from Regen.
If the CSHC is the semi-finals, the AACR annual meeting would be the World-Series....22APR, Pennsylvania for abstract presentation!
http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=3682&sKey=d159ef6b-e47f-402a-9a14-1c3bbdff5bfb&cKey=711f053f-2ff6-4320-849c-62b885a1fb6f&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424
The American Association for Cancer Research (AACR) is the world's oldest and largest professional association related to cancer research. The AACR Annual Meeting attracts more than 18,000 participants from around the world and has been described as the "main forum to present and discuss cancer-related research." - Wikipedia.
The AACR Foundation for the Prevention and Cure of Cancer directly funds research that holds promise for a cure for cancer. The foundation's mission to "accelerate progress in the conquest of cancer by providing financial support for scientific research, education, and communication" is demonstrated by its support of scientists at all levels.
Roche's vesanoid, for APL, currently the only differentiation based therapeutic on the market with FDA approval? Roche's 2014 acquisitions indicates strong IP expansion in this field...Diffron-C with Ichims two patented complementary novel molecules can prove even more effective against APL...what the heck is RGBP doing on the OTC, this science is worth hundreds of millions alone, if we were nasdaq this would be steadily increasing as the pipeline develops, one day the OTC will realize the value here
60 minutes segment, Dr. Marks, deputy director for immunotherapy at the FDA....immunotherapy is a paradigm shift....
Ken Burns " mysteries of cancer" 3 part series on PBS starts on Monday, immunotherapy will be discussed, gonna tivo it...,GoT season 5 in a couple weeks as well!!!
How many years has it been since the OTC has seen an FDA approved IND....we will show them something they have never seen before...for now we may be bootstrapping the sisters but their momentum will be enough to launch us here as well
1% elite status here, see everyone at the top, think we start moving once GLP safety studies are sent to FDA...Ichims prepping the clinical phase 1, juniors conducting pre-clinical experiments, wild cards are orphan and ENTB...
William Wallace says HOLD, HOLD and if you want your freedom, he told me to add all three of the sisters this week! I figure i might as well, as this is my island!
Welcome Kbro, Entb all the way! We will be seeing chart tripping volume here! Dr Koos will right this flight like Denzel!
Will be grabbing more this week Sizzle, the trifecta has a Royal Flush draw, gonna be a 1 % holder here for .02+
CEO Koos is posting PRs on a consistent basis, 2 per month, keeping us and potential investors informed, what will develop in MAR....now that we have a full time staff, any recent teleconferences, FDA approval will give us a stronger hand at the negotiating table than flexus....